Diagnosis of Multiple Myeloma requires the presence of at least 10% of malignant plasma cells in the bone marrow; these neoplastic cells produce a monoclonal antibody, known as M-protein (monoclonal immunoglobulin protein), as well as other substances, which stimulate osteoclasts and lead to bone tissue resorption [4,7,8]. Here, MYOM2 is linked to plasma cell myeloma.